Parliament Workbench

Question thread · 2 questions

When it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.

Started with S2W-31920 on 21 Feb 2007; latest 10 Sep 2007. Each later question says it follows up an earlier answer.

Follow-ups
1
longest chain 1 step
Span
201 days
21 Feb 2007 to 10 Sep 2007
Answered
2 of 2
by Andy Kerr, Shona Robison
Asked by
2
MSPs

The thread, in order

Each answer’s opening lines; open a question for the full text
  1. S2W-31920 21 Feb 2007 Alasdair Morgan SNP Answered

    To ask the Scottish Executive when it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.

    Andy Kerr, 27 Feb 2007: Lucentis® (ranibizumab) was approvedon 22 January 2007 by the European Medicines Evaluation Agency (EMEA). the Scottish Medicines Consortium have this therapy on their work programme and a recommendationis anticipated from them in the next few months.
  2. S3W-04180 10 Sep 2007 Des McNulty Lab Answered

    Whether, following the approval of Lucentis® (ranibizumab) on 22 January 2007 by the European Medicines Evaluation Agency, the Scottish Medicines Consortium has made a recommendation regarding the use of this therapy.

    Shona Robison, 18 Sep 2007: The ScottishMedicines Consortium recommended Lucentis for use in NHS Scotland on 11 June 2007. Further information is available at: www.scottishmedicines.org.

How this thread is put together

Follow-up
A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
Several citations
When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
Thread
Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.

All question threads